Cannabis Dependence Clinical Trial
Official title:
Open-Label Pilot Study of Quetiapine Treatment for Cannabis Dependence
Marijuana is the most commonly used illicit drug in the United States. However, the treatment
options for cannabis dependence are limited; notably, no effective pharmacotherapy has been
developed. Conceptually, the ideal medication treatment for cannabis dependence would:
1. be safe when administered to patients actively using cannabis
2. reduce cannabis intake and promote abstinence
3. treat the symptoms of cannabis withdrawal
4. reduce craving and relapse risk
5. have a low abuse liability.
Conceptually, the pharmacodynamic and clinical actions of quetiapine suggest that it may be useful for cannabis dependence. By antagonizing dopamine, quetiapine may interfere with the reinforcing effects of cannabis, while serotonin type 2A, histamine type 1, and adrenergic receptor antagonism may reduce cannabis withdrawal symptoms, primarily by sedating and anxiolytic effects. The proposed research project is an open-label pilot study to evaluate the tolerability and ideal target dosing range for quetiapine treatment of cannabis dependence over an eight-week period. The purpose of this pilot study is to obtain preliminary data regarding the potential efficacy, tolerability and safety of quetiapine treatment of cannabis dependence before conducting a larger double-blind trial. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01005810 -
A Trial of N-Acetylcysteine (an Over-the-Counter Medicine) in Adolescents Who Smoke Marijuana
|
Phase 2 | |
| Completed |
NCT00114439 -
Lithium Cannabis Withdrawal Study
|
Phase 2 | |
| Completed |
NCT00350285 -
The Teen Marijuana Check-Up
|
Phase 2 | |
| Completed |
NCT01618656 -
Safety and Efficacy of a FAAH-Inhibitor to Treat Cannabis Withdrawal
|
Phase 2 | |
| Completed |
NCT01153490 -
Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine
|
Phase 4 | |
| Completed |
NCT02946489 -
Facilitating the Behavioral Treatment of Cannabis Use Disorder
|
Phase 1 | |
| Completed |
NCT02088177 -
Study of Long-Acting Injectable Naltrexone to Treat Cannabis Dependence
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT01565174 -
The Pharmaco-genetic and Brain Mechanisms Associated With Cannabis- Induced Psychosis
|
N/A | |
| Completed |
NCT01697709 -
Quetiapine Pharmacotherapy for Cannabis Dependence
|
Phase 2 | |
| Recruiting |
NCT04721353 -
Reducing Cannabis Overuse With Prazosin
|
Phase 4 | |
| Completed |
NCT01603992 -
Quiting Marijuana Use: Self-report Study of Quitting Straegies and Withdrawal Symptoms
|
||
| Completed |
NCT00167297 -
Atomoxetine for the Treatment of Cannabis Dependence
|
Phase 2 | |
| Terminated |
NCT01598896 -
Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia
|
Phase 2/Phase 3 | |
| Completed |
NCT01611948 -
Treatment for Cannabis Withdrawal and Dependence
|
Phase 2 | |
| Recruiting |
NCT03221231 -
N-acetylcysteine for the Treatment of Cannabis Dependence: Working Mechanisms
|
Phase 4 | |
| Not yet recruiting |
NCT03366909 -
Mindfulness Meditation and Cannabis Dependence : Therapy Effectiveness
|
N/A | |
| Completed |
NCT01639872 -
Clozapine for Cannabis Use in Schizophrenia
|
Phase 4 | |
| Not yet recruiting |
NCT06334016 -
Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream
|
Early Phase 1 | |
| Completed |
NCT01793961 -
Effects of Chronic Intake of Cannabis on Contrast Sensitivity
|
N/A | |
| Completed |
NCT01747850 -
Sativex and Behavioral-relapse Prevention Strategy in Cannabis Dependence
|
Phase 2 |